Self-Reported Use of Non-FDA Approved Cannabinoid Products Among Hospitalized Patients in a Large U.S. Hospital Network

The growing cannabinoid product (CP) market and its increasing public accessibility have generated unique regulatory challenges. This poster summarizes a cross-sectional descriptive study which explored patient self-reported use of non-FDA-approved CP prior to admission in a large U.S. hospital network. It was presented at the 2025 ISPE Annual Meeting,